Continuing the race adjustment factors maintains health care disparities, the authors noted.
Clinicians should stop using the race adjustment factor in pulmonary function testing (PFT), according to a recent entry in the Things We Do for No Reason series in the Journal of Hospital Medicine.
The authors wrote that adjusting spirometry values stems from old studies about differences in lung function among races, which were then applied to testing. As a result, lung volume reference values for Black patients are 10% to 15% lower than values for White patients.
There are 3 reasons why the race adjustment factor in PFT is injurious to patients, the authors wrote:
“The medical community should follow the lead of other equations, like estimated glomerular filtration rate and the vaginal birth after cesarean calculator, which have successfully removed race factors,” the authors wrote.
Continuing race adjustment maintains health care disparities, they said, and any concerns about the possibility of overdiagnosing disease must be outweighed by the harm that comes from underdiagnosing it.
They called upon clinicians to:
“As a profession, we must practice race-conscious medicine that values individualized care, recognizes the contributions of structural racism and social determinants in patient health, and standardize care when possible, based on objective metrics,” they wrote.
The Things We Do for No Reason series is inspired by the Choosing Wisely program, which seeks to promote high-value care by educating clinicians and the public about low-value care.
Reference
Beaverson S, Ngo VM, Pahuja M, Dow A, Nana-Sinkham P, Schefft M. Things We Do for No Reason: race adjustments in calculating lung function from spirometry measurements. J Hosp Med. Published online October 7, 2022. 10.1002/jhm.12974
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
January 2nd 2025This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change today.
Read More
2 Commerce Drive
Cranbury, NJ 08512